Translational Cancer Genomics

Precision Cancer Clinic


We offer a consultation clinic for patients with advanced, metastatic cancers for second opinions regarding their cancer. We provide informed consent, discussing risks and benefits of our clinical study, OSU-13053: Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing (NCT02090530). Interested patients must inquire with their hematologist/oncologists first to determine whether they are eligible for such a study.

Precision Tumor Board


We coordinate weekly Precision Tumor Board (PTB), to discuss results and interpretation of genomic testing for patients with advanced, metastatic cancer. This format includes multi-disciplinary expertise with medical oncologists, hematologists, pathologist, genomic scientists, computational biologists, genetic counselors, and cancer biologists.

Genomics-Driven Clinical Trials


We participate and develop clinical trials that treat patients with advanced and metastatic cancer based on their molecular features rather than the primary site of disease alone. We develop Investigator-Initiated Trials and also participate in Industry-Sponsored studies through a Genomics-Based Trials Group at OSU’s Comprehensive Cancer Center.

Clinical Grade Genomic Testing: Development


Our lab uses next generation sequencing technologies for both research and clinical sequencing. We develop novel genomic tests that can be migrated and validated in a dedicated clinical grade, CLIA-certified Cancer Genomics Laboratory (CGL). This lab performs testing for clinical trials only and is not a commercial entity or product.


Basic Cancer Research

At Roychowdhury computational biology lab, we are focused on using Next Generation Sequencing (NGS) technologies to sequence cancer-patients’ samples. Through sequencing, we target cancer-specific genes and look for single-nucleotide variants (SNVs), copy-number variants (CNVs), gene expression changes, gene splicing, and chromosomal translocations. We utilize our own custom-designed computational pipelines for exome sequencing and RNA-sequencing analysis. Information gathered from this analysis should help guide proper treatment courses.

Drug Resistance


We study how cancers with genomic alterations become resistant to novel targeted therapies, including but not limited to inhibitors of BRAF, FGFR, PI3K, CDK, RET, and ALK oncogenes. We do this through pre-clinical models of acquired drug resistance and through acquisition of pretreatment and post-progression tumor samples from patients receiving targeted therapies for their cancer treatment.

Discovery


Rare Cancers

We study patients with rare cancers that are so poorly characterized that there are no standard of care treatments for these diseases. We consent them to a clinical study that allows molecular characterization of their cancer using genomic sequencing and other approaches. These studies may lead to novel therapies or applications of existing therapies for patients facing these rare cancers.

Exceptional Responders

During clinical drug development, some trials are considered failures when 20-40% of patients lack obvious benefit from the novel drug. However, selected patients may have an extraordinary response that could be defined by molecular features of their cancer. We seek to evaluate these patients in order to learn what molecular features could predict who might benefit in the future from that therapy.


Cancer Driver Log

CanDL (Cancer Driver Log) is a project relating to the Roychowdhury bioinformatics team's work. It is a database of potentially actionable driver mutations.

Recent advances in next generation sequencing technologies have enabled comprehensive cancer genomic testing by molecular pathologists across multiple tumor types. However, it is often challenging to assign the clinical and biological relevance of specific mutations observed in patients. While there is a multitude of databases that provide in silico assessment, there is no comprehensive database for annotating driver and passenger mutations.

Therefore, we created an expert-curated database of potentially actionable driver mutations for molecular pathologists and laboratory directors to facilitate literature-based annotation of genomic testing of tumors. We curated the chromosome location, all possible nucleotide positions, for each amino acid change and uploaded them to the CanDL database with associated literature reference.

The database currently consists of data on:
  • 60 distinct genes
  • 373 distinct variants

The database is a work in progress, so make sure to visit the CanDL website for the most recent information.

Contact Us

BRT Room 508
460 W. 12th Ave.
Columbus, OH 43210

614-685-5842
roychowdhury.1@osu.edu